{"protocolSection":{"identificationModule":{"nctId":"NCT02485873","orgStudyIdInfo":{"id":"18073"},"secondaryIdInfos":[{"id":"DBOX 2014/00799","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Real-Life Evidence on Stroke Prevention in SPAF","officialTitle":"REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation","acronym":"RELIEF"},"statusModule":{"statusVerifiedDate":"2015-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-05"},"primaryCompletionDateStruct":{"date":"2015-09","type":"ACTUAL"},"completionDateStruct":{"date":"2015-09","type":"ACTUAL"},"studyFirstSubmitDate":"2015-05-28","studyFirstSubmitQcDate":"2015-06-26","studyFirstPostDateStruct":{"date":"2015-06-30","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-11-10","lastUpdatePostDateStruct":{"date":"2015-11-11","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen, LP","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting"},"conditionsModule":{"conditions":["Atrial Fibrillation (Prevention of Stroke)"],"keywords":["Non-valvular atrial fibrillation (NVAF)","Pevention","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":8607,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban","description":"Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]},{"label":"Vitamin K antagonists (VKA)","description":"NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention","interventionNames":["Drug: Vitamin K antagonists"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"As prescribed by treating physicians","armGroupLabels":["Rivaroxaban"]},{"type":"DRUG","name":"Vitamin K antagonists","description":"As prescribed by treating physicians","armGroupLabels":["Vitamin K antagonists (VKA)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)","description":"Composite cardiovascular endpoint","timeFrame":"Within 1 year after treatment start"}],"secondaryOutcomes":[{"measure":"Time to first occurrence of IS","description":"Single cardiovascular event","timeFrame":"Within 1 year after treatment start"},{"measure":"Time to first occurrence of TIA","description":"Single cardiovascular event","timeFrame":"Within 1 year after treatment start"},{"measure":"Time to first occurrence of IH","description":"Single cardiovascular event","timeFrame":"Within 1 year after treatment start"},{"measure":"Time to first occurrence of Other non-traumatic intracranial hemorrhage including subdural hemorrhage","description":"Single cardiovascular event","timeFrame":"Within 1 year after treatment start"},{"measure":"Time to first occurrence of MI","description":"Single cardiovascular event","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of IS","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of TIA","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of IH","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of Other non-traumatic intracranial hemorrhage including subdural hemorrhage","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of MI","timeFrame":"Within 1 year after treatment start"},{"measure":"Incidence density in study population of any of the following: IS, TIA, IH, Other non-traumatic intracranial hemorrhage including subdural hemorrhage, MI","timeFrame":"Within 1 year after treatment start"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age â‰¥18 years on the day of the first prescription of the study drug (= index date) during study selection window\n* Diagnosis of NVAF on start date of study or anytime during 365 days before this date\n* Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date)\n* Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.\n\nExclusion Criteria:\n\n* Patients with valvular AF\n* Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date\n* Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period\n* Prescriptions of \\< 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with non-valvular atrial fibrillation (NVAF)","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Many Locations","country":"Germany"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M13239","name":"Phenprocoumon","relevance":"LOW"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}